# Cytokinetics Inc (CYTK)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/cytokinetics-inc/ JSON: https://steadybase.io/company/cytokinetics-inc.json Checked Nov 10, 2026. Latest filing read: Nov 4, 2026.

## Company

- Legal name: CYTOKINETICS INC
- Ticker: CYTK (Nasdaq)
- SEC CIK: 0001061983
- Industry: Pharmaceutical Preparations (SIC 2834)
- Headquarters: South San Francisco, CA
- Fiscal year ends: December 31
- SEC filer category: Large accelerated filer
- Website: cytokinetics.com
- LinkedIn: https://www.linkedin.com/company/cytokinetics
- Next earnings date: Feb 5, 2027 (estimated from past 8-K timing)

## Key facts

- Revenue: $88.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.html
- Operating income: -$612.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.html
- Net income: -$785.0M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.html
- SG&A: $284.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/0001193125-26-076495-index.html
- Employees: 673 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- Shares outstanding: 139,303,351 as of Nov 2, 2026 (10-Q filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526447408/0001193125-26-447408-index.html
- Auditor: Ernst & Young LLP, San Jose, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm

## Business

We are a biopharmaceutical company focused on discovering, developing and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. We have discovered and are developing muscle-directed investigational medicines that may potentially improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Dec 31, 2025 | $88.0M | -$612.3M | -$785.0M | $284.3M |
| Dec 31, 2024 | $18.5M | -$536.2M | -$589.5M | $215.3M |
| Dec 31, 2023 | $7.5M | -$496.2M | -$526.2M | $173.6M |
| Dec 31, 2022 | $94.6M | -$324.2M | -$389.0M | $178.0M |
| Dec 31, 2021 | $70.4M | -$186.3M | -$215.3M | $96.8M |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/cytokinetics-inc.json

## Officers and directors

- Robert I. Blum, Cytokinetics’ President and Chief Executive Officer. LinkedIn: https://linkedin.com/in/robert-blum. Source: 8-K filed Nov 4, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm
- Sung Lee, EVP, Chief Financial Officer. LinkedIn: https://linkedin.com/in/sung-lee-01b890. Source: Form 4 filed Jul 2, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000106198326000072/0001061983-26-000072-index.htm
- Fady Ibraham Malik, EVP Research & Development. Source: Form 4 filed Sep 22, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000106198326000096/0001061983-26-000096-index.htm
- Andrew Callos, EVP, Chief Commercial Officer. LinkedIn: https://linkedin.com/in/andrew-callos. Source: Form 4 filed Aug 31, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000106198326000090/0001061983-26-000090-index.htm
- Jeffrey Hessekiel, Chief Legal & Admin Officer. Source: Form 4 filed Mar 17, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000106198326000022/0001061983-26-000022-index.htm
- Fady Malik, Executive Vice President, Research & Development. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- Eric Brown, Vice President of Information Technology. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- Edward M. Kaye, M.D., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm
- James M. Daly, Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm
- John T. Henderson, M.B., Ch.B., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm
- Robert A. Harrington, M.D., Board member (per proxy). Source: DEF 14A filed Apr 17, 2026, https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm

## Recent 8-K events

- Nov 4, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-20261104.htm
- Aug 28, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-20260828.htm
- Aug 13, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526348060/cytk-20260813.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526338021/cytk-20260806.htm
- May 27, 2026: Item 5.07, Submission of matters to a vote of security holders. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526241840/cytk-20260527.htm
- May 8, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526214606/d138544d8k.htm
- May 5, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526206420/d124879d8k.htm
- May 5, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526206360/cytk-20260505.htm
- Feb 24, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526067012/cytk-20260224.htm
- Feb 17, 2026: Item 8.01, Other events. Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526053049/cytk-20260217.htm

## Insider trades (Form 4)

- Nov 3, 2026: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares, about $220,255. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000108/0001061983-26-000108-index.htm
- Nov 2, 2026: Robert I. Blum (President & CEO) sold 7,500 shares, about $471,075. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000107/0001061983-26-000107-index.htm
- Oct 20, 2026: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares, about $224,035. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000100/0001061983-26-000100-index.htm
- Oct 12, 2026: Robert I. Blum (President & CEO) sold 7,500 shares, about $471,600. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000099/0001061983-26-000099-index.htm
- Oct 6, 2026: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares, about $214,830. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000098/0001061983-26-000098-index.htm
- Sep 28, 2026: Robert I. Blum (President & CEO) sold 7,500 shares, about $490,950. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000097/0001061983-26-000097-index.htm
- Sep 22, 2026: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares, about $239,015. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000096/0001061983-26-000096-index.htm
- Sep 15, 2026: Robert E. Landry (Director) sold 1,000 shares, about $72,130. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000095/0001061983-26-000095-index.htm
- Sep 15, 2026: Robert I. Blum (President & CEO) sold 105,426 shares, about $7.3M. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000094/0001061983-26-000094-index.htm
- Sep 11, 2026: Robert E. Landry (Director) sold 1,000 shares, about $74,660. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000093/0001061983-26-000093-index.htm
- Sep 8, 2026: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares, about $264,110. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000092/0001061983-26-000092-index.htm
- Sep 1, 2026: B. Lynne Parshall (Director) sold 5,000 shares, about $357,400. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000091/0001061983-26-000091-index.htm
- Aug 31, 2026: Andrew Callos (EVP, Chief Commercial Officer) sold 10,000 shares, about $702,400. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000090/0001061983-26-000090-index.htm
- Aug 31, 2026: Robert I. Blum (President & CEO) sold 7,500 shares, about $526,800. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000089/0001061983-26-000089-index.htm
- Aug 18, 2026: Fady Ibraham Malik (EVP Research & Development) sold 3,500 shares, about $265,370. Source: https://www.sec.gov/Archives/edgar/data/1061983/000106198326000088/0001061983-26-000088-index.htm

## What management said

- "Our third quarter results demonstrate continued strong execution as Cytokinetics enters its next phase of growth as a global specialty cardiology biopharmaceutical company" Robert I. Blum, Cytokinetics’ President and Chief Executive Officer (8-K filed Nov 4, 2026). Source: https://www.sec.gov/Archives/edgar/data/1061983/000119312526447198/cytk-ex99_1.htm

## Latest filings

- 8-K filed Aug 28, 2026: https://www.sec.gov/Archives/edgar/data/1061983/000119312526372456/cytk-20260828.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1061983/000119312526076495/cytk-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1061983/000119312526338217/cytk-20260630.htm
- DEF 14A filed Apr 17, 2026: https://www.sec.gov/Archives/edgar/data/1061983/000114036126015364/ny20063687x771_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/